Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate disappointed in phase 2, disclosed (PDF) the setback as part of a wider ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data.

Roche CEO: not good to limit competition in this space Roche says not itself, but others affected by Catalent deal Swiss drugmaker joins US peer Lilly in voicing opposition Eli Lilly and advocacy ...

MANSFIELD — Roche Bros Supermarkets Inc., a 20-store eastern Massachusetts grocery chain under the Roche Bros., Sudbury Farms and Brothers Marketplace banners, said it has entered into a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Speaking to the press Wednesday, Roche’s chief executive Thomas Schinecker critiqued the proposed transaction, arguing that it could hamper the ability of smaller biopharma players to lock down ...

FRANKFURT, Oct 23 (Reuters) - The CEO of Roche (ROG.S), opens new tab said he has been informed that more cases of mpox infection have occurred in Europe than previously reported and that the ...

Martin Gleize, international director at Roche Bobois, shares the story of the company and what sets it apart from the other furniture brands out there.

Roche is reported to be considering the sale of its cancer data specialist Flatiron Health, just a few years after it bought the company for $1.9 billion. The Financial Times first revealed the ...

Brian Roche co-anchors News 8 at 5 p.m. each weekday. He is also the 8 On Your Side Consumer/Investigative reporter for News 8. Brian is an Emmy Award winning anchor and reporter. He has been ...

Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.1 billion takeover of Carmot Therapeutics as it tries to catch up with the leaders in the fast ...